Clinuvel Pharmaceuticals (ASX:CUV): Nearly 7 years on from the FDA’s approval of Scenesse, this company is now at a crossroads

Clinuvel Pharmaceuticals (ASX:CUV) is a perculiar company. It is a rare example of an Australian biotech that not only survived the long march from discovery to approval but did so with discipline, profitability and independence. Its 2019 FDA approval for Scenesse was the defining moment in its history, the point at which a decades‑long scientific and regulatory struggle finally crystallised into commercial reality.

But it is perculiar because it has not gone on the same road as Telix and Neuren. Unlike the latter pair, the years since Clinuvel’s watershed FDA approval have not been as smooth as many investors expected. The company has remained profitable, debt‑free and cash‑rich, but its share price has drifted, its investor base has become restless and its pipeline has advanced more slowly than hoped. The question now is whether the future looks brighter than the recent past, and whether Clinuvel’s next decade can deliver the growth that the last five years have not.

Clinuvel Pharmaceuticals: A 3-decade journey to Scenesse’s approval

Clinuvel’s story begins in the late 1980s, when afamelanotide was first explored as a tanning agent. The early scientific work was promising, but the regulatory environment was hostile. The FDA rejected the idea of a cosmetic injectable outright, and for years the molecule sat in a commercial no‑man’s‑land. The company, then known as Epitan, listed on the ASX in 2000 with the tanning concept still alive, but the FDA’s position never softened. By the mid‑2000s, the company was running out of time.

The turning point came with a strategic pivot. Under Philippe Wolgen, Clinuvel abandoned the cosmetic positioning and reframed afamelanotide as a treatment for erythropoietic protoporphyria, a rare genetic disorder that causes extreme light sensitivity and debilitating pain. The scientific rationale was strong, and early Swiss trials showed dramatic improvements in sunlight tolerance. European regulators were receptive, and by 2014 the European Medicines Agency approved Scenesse for adult EPP patients. Commercialisation began in Europe in 2016, and Clinuvel became one of the few ASX biotechs to generate meaningful revenue from an orphan drug.

The real milestone, however, was the 2019 FDA approval. Scenesse became the first drug approved in the United States for EPP, and the share price surged. For a moment, Clinuvel looked like a global rare‑disease success story. It had achieved what most biotechs never do: approval in both Europe and the US, reimbursement in multiple jurisdictions, and a profitable business model built on a single molecule.

Yet the years after 2019 did not unfold as investors expected. The company remained profitable, but revenue growth slowed. The US rollout was steady rather than explosive. In FY25, it made A$105.3m and a $36.2m post-tax profit compared with $83m revenue and a $30.6m profit 2 years prior. Not bad at first glance. And it paid a dividend of $0.05 per share in each of the last 3 years.

The pipeline advanced, but not at the pace the market wanted. If one thing stands out to us, is that its cash rose from $156.8m to $224.1m in 2 years – that’s a big pile. Implication: it didn’t invest as much into its R&D as investors wanted. The company’s argument is it was good to have for a rainy day.

But investor sentiment cooled, and the share price fell from its all-time highs. The company’s AGM saw its first remuneration strike in 2023 followed by its second in 2024. The votes against the remuneration report were 39.7% in the first year and 52.2% in the second with the latter requiring a board spill. Although the spill did not occur as only 10% of votes were in favour, questions emerged about succession planning, communication and long‑term strategy.

The bottom line is that Clinuvel had achieved the hardest part, but the next phase proved more complicated.

Clinuvel’s future that could be rosier, but only if execution improves

Clinuvel’s future depends on whether it can convert its pipeline into commercial products. The company has positioned itself as a “house of melanocortins”, with multiple assets built around melanocortin biology. The strategy is coherent, but execution risk is real.

The most important pipeline opportunity is vitiligo. The global patient population is large (several times more than EPP), and repigmentation therapies represent a multi‑billion‑dollar market. Clinuvel’s approach combines afamelanotide with UVB phototherapy, and early studies have shown repigmentation in darker‑skinned patients.

The company is running a phase III trial and preparing follow‑on studies. If successful (and there’s a high chance we could find out in the next 12 months), vitiligo could transform Clinuvel from a niche orphan‑drug company into a mid‑cap dermatology player. But the challenges are significant. Regulatory pathways are complex, cultural considerations around skin darkening matter, and competition from JAK inhibitors is intensifying. Vitiligo is a high‑impact opportunity, but not a guaranteed one.

Xeroderma pigmentosum is another pipeline strand. XP is ultra‑rare, but the medical need is severe. Clinuvel is running two phase II studies aimed at improving photoprotection and reducing skin‑cancer burden. XP will not deliver large commercial returns, but it strengthens Clinuvel’s rare‑disease credentials and builds regulatory goodwill. It is strategically useful even if financially modest.

Prenumbra is the moonshot. It is a fast‑acting afamelanotide analogue designed for acute vascular events, including arterial ischaemic stroke. The market is enormous, and the clinical impact could be profound. But stroke trials are difficult, endpoints are complex and regulatory conservatism is high. Prenumbra is the highest‑risk, highest‑reward part of the pipeline. If it succeeds, Clinuvel’s valuation would be reshaped. If it fails, the company remains dependent on dermatology and photomedicine.

The final strand is the melanocortin franchise, including Neuracthel and Cyacelle. Neuracthel is Clinuvel’s ACTH‑based repigmentation therapy, designed to complement afamelanotide in vitiligo. Cyacelle is an OTC photoprotective product aimed at high‑risk populations. These products diversify revenue and reduce reliance on Scenesse, but their commercial impact will depend on branding, distribution and regulatory positioning. They are useful additions, but they are not transformational on their own.

The future could be rosier than the recent past, but only if Clinuvel executes across multiple fronts: vitiligo trials, XP studies, Prenumbra development, OTC product rollout and US centre expansion. The company has the cash, the scientific foundation and the regulatory track record. What it needs now is momentum.

What consensus estimates say about the next five years

Consensus estimates provide a window into how analysts perceive Clinuvel’s trajectory. They show modest growth in the near term, followed by a dramatic jump in 2029 and a decline in 2030. The pattern reflects both caution and optionality.

In FY26 (the year which will be reported on this reporting season), analysts expect revenue of A$99.46m and EBITDA of A$41.75m, with earnings per share of A$0.72. With 50.4 m shares on issue, that translates to profit of roughly A$36.3 m. In fiscal 2027, revenue is expected to rise to A$105.36 m and EBITDA to A$44.47 m, with a A$38.8m profit.

Looking ahead to 2029, analysts expect revenue to surge to A$278.81 m and EPS to jump to A$2.79, implying a profit of about A$140.6 m. The magnitude of the jump suggests analysts are modelling a major product approval, most likely vitiligo. The size of the increase is too large to be explained by EPP expansion or OTC products. It reflects the belief that Clinuvel’s pipeline has real commercial potential, even if analysts are not yet confident enough to model sustained growth beyond the launch year.

These estimates put it at 13x P/E for FY27. However…its PEG is nearly 3x.

Conclusion

Clinuvel is a company at a crossroads. Its history is remarkable. It achieved what few biotechs do: approval in Europe and the US, reimbursement across multiple jurisdictions, profitability, dividends and independence. Its 2019 FDA approval was the culmination of decades of work. But the years since have been challenging. Revenue growth has slowed, investor sentiment has cooled and the share price has drifted.

The future, however, is not bleak. The pipeline is real. Vitiligo has the potential to reshape the company. XP strengthens its rare‑disease positioning. Prenumbra offers transformational upside. The melanocortin franchise diversifies revenue. Consensus estimates show a belief amongst analysts that the company is undervalued and that pipeline success could materially increase earnings.

Whether Clinuvel is a buy depends on the investor’s risk appetite. The company is profitable, cash‑rich and disciplined. It has a strong regulatory track record and a coherent scientific strategy. But pipeline execution is uncertain, and the next two years will be critical. Investors who believe in the melanocortin platform and are willing to wait for clinical readouts may see value. Investors who want near‑term growth may find the pace too slow.

On balance, Clinuvel is a company in a transition rather than stagnation even if it seems the latter would be more fair. The next phase will determine whether it becomes a mid‑cap global dermatology and photomedicine player or remains a niche orphan‑drug business. The optionality is real, but so are the risks. Investors should weigh both carefully.